.

  • Lonza appoints Maria Soler Nunez as Head, Group Operations
  • Maria joins Lonza from Novartis where she has led the quality organization since 2020
  • Maria will commence her tenure with Lonza Group on 1 August 2022, succeeding Stefan Stoffel, who is retiring from Lonza

Lonza today announced that its Board of Directors has appointed Maria Soler Nunez as the new Head, Group Operations. The appointment will be effective from 1 August 2022. Maria will succeed Stefan Stoffel as a member of the Lonza Group Executive Committee.

Maria joins Lonza Group from Novartis where she has worked since 2010, holding a succession of leadership positions in quality and operations. In her most recent role, Maria led the Novartis quality organization as Chief Quality Officer. In this role, Maria was responsible for all aspects of quality, and was leading an organization of 7,000 associates across preclinical, clinical, TechOps, commercial and Quality Systems functions.

Albert M. Baehny, Chairman, Lonza, commented: “We are looking forward to welcoming Maria to the Lonza Group Executive Committee. Maria’s extensive experience in quality and manufacturing operations will be a great asset as we continue to focus on customer delivery and advance on our ambitious growth journey.”

Pierre-Alain Ruffieux, CEO, Lonza, added: “Maria brings an impressive track record in operations and quality to Lonza. I am greatly looking forward to working with her as we continue our focus on operational excellence and long-term value creation.”

Prior to her most recent role, Maria held multiple roles at Novartis including Head of Global Manufacturing Functions, and Global Head of Manufacturing, Science & Technology.

Maria holds a graduate degree in Pharmacy Studies and a PhD. in Pharmacy from the Universidad Complutense de Madrid. She also holds a Postgraduate Degree in Design and Statistics for Medical Sciences from the Universidad Autónoma de Barcelona.

Following a handover, Maria will succeed Stefan Stoffel, who has decided to retire. Stefan has held a variety of leadership roles during a career with Lonza spanning more than three decades. Stefan has worked in multiple locations and roles during his extensive career. In his most recent role, Stefan has led Group Operations since January 2021. As a member of the Lonza Group Executive Committee, Stefan has made a valuable contribution to many strategic projects as well as overseeing many important growth and delivery programs that has supported the company’s long-term growth and success.

Stefan will commence his retirement on 1 August, 2022. The Lonza management would like to thank Stefan for his significant contribution during his long tenure and wish him an enjoyable and well-deserved retirement.

Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Über Lonza Group Ltd.

Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare industry.

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 16,000 employees (full-time equivalent), we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 5.4 billion with a CORE EBITDA of CHF 1.7 billion in Full-Year 2021. Find out more at www.lonza.com

Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter

Firmenkontakt und Herausgeber der Meldung:

Lonza Group Ltd.
Münchensteinerstraße 38
CH4002 Basel
Telefon: +41 (61) 3168638
Telefax: +41 (61) 3169638
http://www.lonza.com

Ansprechpartner:
Dirk Oehlers
Telefon: +41 (61) 316-8540
Fax: +41 (61) 316-9540
E-Mail: dirk.oehlers@lonza.com
Victoria Morgan
Head of Corporate Communications
Telefon: +41 (79) 599-6260
E-Mail: victoria.morgan@lonza.com
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel